675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)A. Dimitrios Colevas, Douglas Adkins, Katie Kerrigan et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)A. Dimitrios Colevas, Douglas Adkins, Kathleen Kerrigan et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 1
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.A. Dimitrios Colevas, Douglas Adkins, José Dinis et al.|Journal of Clinical Oncology|2023Cited by 0
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker CorrelativesRobert L. Ferris, Julie E. Bauman, Farzan Siddiqui et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0
Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)Julie E. Bauman, Robert L. Ferris, J. Harris et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0